Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354963 | 1.00 | OPRK1 (0.49) | OPRK1HRH3ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL354962 | 1.00 | OPRK1 (0.49) | OPRK1HRH3ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL354878 | 0.99 | OPRK1 (0.50) | OPRK1HRH3ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL354877 | 0.99 | OPRK1 (0.50) | OPRK1HRH3ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4776245 | 0.93 | OPRK1 (0.53) | OPRK1ALDH1A1PLAUKDM4EDRD2 | |
| SCHEMBL1725563 | 0.88 | HRH3 (0.53) | HRH3ALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL5634205 | 0.87 | LMNA (0.49) | OPRK1PLAUPRMT6DRD2DRD3 | |
| SCHEMBL5633241 | 0.87 | OPRK1 (0.48) | OPRK1HRH3ALDH1A1PLAUDRD2 | |
| SCHEMBL5633787 | 0.86 | OPRK1 (0.50) | OPRK1HRH3ALDH1A1POLBPLAU | |
| SCHEMBL4780284 | 0.86 | OPRK1 (0.47) | OPRK1HRH3PLAUDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304065-B2 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | claimed |
| EP-1667958-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005033063-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-07 | — | — | US | claimed |
| EP-2403854-B1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | GRUENENTHAL GMBH (DE) | 2013-09-11 | — | — | EP | disclosed |
| EP-2403854-B1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | GRUENENTHAL GMBH (DE) | 2013-09-11 | — | — | EP | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| EP-2403854-A1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | Grünenthal GmbH (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-1656355-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1878728-A2 | Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders | Amgen Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7304065-B2 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | disclosed |
| EP-1667958-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005033063-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | OPRK1 28/4885HRH3 1002/4885ALDH1A1 353/4885 |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | OPRK1 90/4885HRH3 781/4885ALDH1A1 3383/4885 |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | OPRK1 90/4885HRH3 781/4885ALDH1A1 3383/4885 |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | BDKRB1, BDKRB2, KCNB1 | OPRK1 167/4885HRH3 133/4885ALDH1A1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.